לפניכם הרצאות מתוך כנס ההשקה של טרוליסיטי בישראל | אפריל 2016
Shaping the paradigm in T2D treatment –
transitioning to injectable
therapy, real Life experience with Trulicity.
Prof. Michael Nauck
Head, Clinical Research, Division of Diabetology Medical Department I St. Josef-Hospital, Germany
Head, Clinical Research, Division of Diabetology Medical Department I St. Josef-Hospital, Germany
Starting GLP-1RA, introduction of dulaglutide
Dulaglutide - clinical effectiveness vs. other GLP-1RA
GLP-1RA- Systematic analysis: safety, tolerability and individualized approach
Trulicity - advancements in GLP1RA - bringing the latest data
into clinical practice.
Prof. Francesco Giorgino
Director, Postgraduate School in Endocrinology and Metabolic Diseases
University of Bari Aldo Moro. Chief, Division of Endocrinology University
Hospital Policlinico Consorziale. Italy.
Director, Postgraduate School in Endocrinology and Metabolic Diseases
University of Bari Aldo Moro. Chief, Division of Endocrinology University
Hospital Policlinico Consorziale. Italy.
GLP-1RA -Similarities and differences among the class
GLP-1RA vs. Insulin in T2D, focus on dulaglutide
Adherence to diabetes medications
